Nastaran Khodadad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nastaran Khodadad has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Shokufeh Akbarinia
Shiraz University of Medical Sciences
4 shared publicationsAva Hashempour
HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran
3 shared publicationsFarzane Ghasabi
HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran
2 shared publicationsMohamad Matin Karbalaei Ali Nazar
HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran
2 shared publications- Shahab Falahi
Zoonotic Diseases Research Center Ilam University of Medical Sciences Ilam Iran
2 shared publications Younes Ghasemi
Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2 shared publications
Latest Publications
- 4 March 2026
- Published by Taylor & Francis in Future Virology
- Vol. 21 (3) , 219-234
The role of lipid molecules in the pathogenesis of viral gastroenteritis
- 4 March 2026
- Published by Taylor & Francis in Future Virology
- Vol. 21 (3) , 219-234
The role of lipid molecules in the pathogenesis of viral gastroenteritis
- Open Access
- 17 February 2025
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 41, 101939
Prediction of the Co-receptor usage of the main worldwide HIV-1 subtypes, CRF, and CRF35-AD in Iranian patients via the five genotypic tools
- 17 February 2025
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 41, 101939
Open AccessPrediction of the Co-receptor usage of the main worldwide HIV-1 subtypes, CRF, and CRF35-AD in Iranian patients via the five genotypic tools
- Open Access
- 20 September 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1
Correction: Reverse vaccinology approaches to design a potent multiepitope vaccine against the HIV whole genome: immunoinformatic, bioinformatics, and molecular dynamics approaches
- 20 September 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1
Open AccessCorrection: Reverse vaccinology approaches to design a potent multiepitope vaccine against the HIV whole genome: immunoinformatic, bioinformatics, and molecular dynamics approaches
- Open Access
- 28 August 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-21
Reverse vaccinology approaches to design a potent multiepitope vaccine against the HIV whole genome: immunoinformatic, bioinformatics, and molecular dynamics approaches
Substantial advances have been made in the development of promising HIV vaccines to eliminate HIV-1 infection. For the first time, one hundred of the most submitted HIV subtypes and CRFs were retrieved from the LANL database, and the consensus sequences of the eleven HIV proteins were obtained to design vaccines for human and mouse hosts. By using various servers and filters, highly qualified B-cell epitopes, as well as HTL and CD8 + epitopes that were common between mouse and human alleles and were also located in the conserved domains of HIV proteins, were considered in the vaccine constructs. With 90% coverage worldwide, the human vaccine model covers a diverse allelic population, making it widely available. Codon optimization and in silico cloning in prokaryotic and eukaryotic vectors guarantee high expression of the vaccine models in human and E. coli hosts. Molecular dynamics confirmed the stable interaction of the vaccine constructs with TLR3, TLR4, and TLR9, leading to a substantial immunogenic response to the designed vaccine. Vaccine models effectively target the humoral and cellular immune systems in humans and mice; however, experimental validation is needed to confirm these findings in silico.
- 28 August 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-21
Open AccessReverse vaccinology approaches to design a potent multiepitope vaccine against the HIV whole genome: immunoinformatic, bioinformatics, and molecular dynamics approaches
Substantial advances have been made in the development of promising HIV vaccines to eliminate HIV-1 infection. For the first time, one hundred of the most submitted HIV subtypes and CRFs were retrieved from the LANL database, and the consensus sequences of the eleven HIV proteins were obtained to design vaccines for human and mouse hosts. By using various servers and filters, highly qualified B-cell epitopes, as well as HTL and CD8 + epitopes that were common between mouse and human alleles and were also located in the conserved domains of HIV proteins, were considered in the vaccine constructs. With 90% coverage worldwide, the human vaccine model covers a diverse allelic population, making it widely available. Codon optimization and in silico cloning in prokaryotic and eukaryotic vectors guarantee high expression of the vaccine models in human and E. coli hosts. Molecular dynamics confirmed the stable interaction of the vaccine constructs with TLR3, TLR4, and TLR9, leading to a substantial immunogenic response to the designed vaccine. Vaccine models effectively target the humoral and cellular immune systems in humans and mice; however, experimental validation is needed to confirm these findings in silico.
- 1 August 2024
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 40 (8) , 471-481
Frequency of Fusion Inhibitor Resistance Mutations Among Therapy-Naïve HIV Patients
Background Glycoprotein 41 (gp41) of the human immunodeficiency virus type 1 (HIV-1) protein plays a critical role in membrane fusion. Gp41 binds to proteins in the plasma membrane of CD4+ T cells, particularly the T-cell antigen receptor (TCR). These findings indicate that gp41 is involved in the assembly of HIV-1 at the plasma membrane of T cells and affects the stimulation of the TCR. To control HIV-1, new inhibitors were introduced to target the gp41 protein. However, mutations in this region might reduce their efficacy. Materials and Methods The Gp41 region was amplified from the sera of thirty patients using nested polymerase chain reaction (PCR). The sequences were analyzed by bioinformatics tools to identify mutations and gp41 structural features. Subtyping and the interaction between fusion inhibitors and gp41 proteins were also examined. Results As the first report from Iran, docking analysis between fusion inhibitors and Iranian gp41 proteins showed that mutations in gp41 could not reduce the efficacy of the fusion inhibitors. Most of the patients were infected with CRF35-AD. Several postmodification positions, including glycosylation and phosphorylation sites, were identified in the gp41 protein. Conclusion Our findings revealed no known multinational drug resistance to gp41 inhibitors; thus, fusion inhibitors can effectively inhibit HIV in Iranian patients. Additionally, the present study introduced a new gp41 region (36-44 aa), which considerably influences the interactions between gp41 inhibitors and the gp41 protein. This region may play a pivotal role in suppressing gp41 inhibitors in CFR35-AD. Furthermore, gp41 can be considered a good target for subtyping analysis via the phylogenetic method.
- 1 August 2024
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 40 (8) , 471-481
Frequency of Fusion Inhibitor Resistance Mutations Among Therapy-Naïve HIV Patients
Background Glycoprotein 41 (gp41) of the human immunodeficiency virus type 1 (HIV-1) protein plays a critical role in membrane fusion. Gp41 binds to proteins in the plasma membrane of CD4+ T cells, particularly the T-cell antigen receptor (TCR). These findings indicate that gp41 is involved in the assembly of HIV-1 at the plasma membrane of T cells and affects the stimulation of the TCR. To control HIV-1, new inhibitors were introduced to target the gp41 protein. However, mutations in this region might reduce their efficacy. Materials and Methods The Gp41 region was amplified from the sera of thirty patients using nested polymerase chain reaction (PCR). The sequences were analyzed by bioinformatics tools to identify mutations and gp41 structural features. Subtyping and the interaction between fusion inhibitors and gp41 proteins were also examined. Results As the first report from Iran, docking analysis between fusion inhibitors and Iranian gp41 proteins showed that mutations in gp41 could not reduce the efficacy of the fusion inhibitors. Most of the patients were infected with CRF35-AD. Several postmodification positions, including glycosylation and phosphorylation sites, were identified in the gp41 protein. Conclusion Our findings revealed no known multinational drug resistance to gp41 inhibitors; thus, fusion inhibitors can effectively inhibit HIV in Iranian patients. Additionally, the present study introduced a new gp41 region (36-44 aa), which considerably influences the interactions between gp41 inhibitors and the gp41 protein. This region may play a pivotal role in suppressing gp41 inhibitors in CFR35-AD. Furthermore, gp41 can be considered a good target for subtyping analysis via the phylogenetic method.
- 23 September 2021
- Published by Taylor & Francis in Future Virology
- Vol. 16 (10) , 667-675
Molecular Characterization and Phylogenetic Analyses of full-length Viral Genomes From Iranian Patients With Chronic Hepatitis B Virus
Aim: Chronic hepatitis B infection is the main cause of liver complications such as hepatic failure, liver cirrhosis and hepatocellular carcinoma (HCC). In this study, we attempted to evaluate mole...
- 23 September 2021
- Published by Taylor & Francis in Future Virology
- Vol. 16 (10) , 667-675
Molecular Characterization and Phylogenetic Analyses of full-length Viral Genomes From Iranian Patients With Chronic Hepatitis B Virus
Aim: Chronic hepatitis B infection is the main cause of liver complications such as hepatic failure, liver cirrhosis and hepatocellular carcinoma (HCC). In this study, we attempted to evaluate mole...